Gemini tf 16 astonish

Images were acquired on a PET/CT device (Gemini TF 16 Astonish, Philips Medical Systems, Cleveland, OH, USA). Patients were examined in supine position from base of scull to the proximal femora 62 ± 35 min after intravenous injection of 113 ± 13.3 MBq of [⁶⁸Ga]PSMA-HBED-CC (PSMA-11) (PSMA). In all patients, a diagnostic, contrast-enhanced CT was acquired and used for attenuation correction. For one patient, no information about injection time and injected dose was available, two patients received radiotherapy planning based on ¹⁸F–Cholin PET, and subsequently underwent PSMA-PET imaging.
The findings in PET imaging were categorized as follows: Local recurrence (T) included recurrence within the prostate bed and seminal vessels. Lymph node metastases within the regional drainage of the prostate was classified as N or as M1a if outside the regional drainage, further metastases (which were in all cases bone metastases) were scored as M1b.

Patients from Xiamen were scanned with a Discovery STE (General Electric Medical Systems, Milwaukee, WI, USA). Data acquisition started 67 ± 22 min (range 50–140 min) after injection of 142–548 MBq FDG (3D PET acquisition, 90 s acquisition time per bed position). PET data were reconstructed using CT-based attenuation-weighted OSEM reconstruction (2 iterations, 20 subsets, 6 mm FWHM Gaussian filter). Voxel size was 4 × 4 × 5 mm.
Patients from Berlin were scanned with a Gemini TF 16 Astonish (Philips Medical Systems, Cleveland, OH, USA). Data acquisition started 71 ± 9 min (range 60–86 min) after injection of 236–248 MBq FDG (3D PET acquisition, 90 s acquisition time per bed position). PET data were reconstructed using BLOB-OS-TF reconstruction (Philips Astonish TF technology: 3 iterations, 33 subsets). Voxel size was 2 × 2 × 2 mm and was re-scaled to 4 × 4 × 5 mm.